Market Overview

UPDATE: Canaccord Genuity Reiterates Perrigo Company at Buy on Launch of Generic Mucinex

Share:
Related PRGO
Michael Kors CEO: We're Actively Looking At M&A Options
Najarian Brothers See Unusual Options Activity In Perrigo And Restoration Hardware
One 20% Dividend Increase Expected Among 8 Announcements In 2nd Half Of February (Seeking Alpha)

Canaccord Genuity maintained Perrigo Company (NASDAQ: PRGO) at Buy with a $128.00 price target.

Canaccord Genuity analyst Randall Stanicky commented, "Perrigo announced this morning the launch of its generic Mucinex 600mg ER tablets ($135M LTM brand sales). Although timing was as expected, we see the launch as a positive for the stock given the prior delay caused by validation issues and what should equate to a ~$40M annual revenue opportunity, or about ~$0.10 to EPS on a full-year basis with what is more incremental benefit anticipated for the March quarter (which we already expect to be strong). […] Trading at ~18.3x NTM P/E, we have yet to see the valuation mean revert, offering room for further multiple expansion."

Perrigo Company closed at $115.98 on Friday.

Latest Ratings for PRGO

DateFirmActionFromTo
Nov 2016Bank of AmericaUpgradesUnderperformNeutral
Aug 2016BarclaysMaintainsOverweight
Aug 2016Deutsche BankMaintainsBuy

View More Analyst Ratings for PRGO
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Reiteration Analyst Ratings

 

Related Articles (PRGO)

View Comments and Join the Discussion!